Journal article

Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery

M Schnurr, QY Chen, A Shin, WS Chen, T Toy, C Jenderek, S Green, L Miloradovic, D Drane, ID Davis, J Villadangos, K Shortman, E Maraskovsky, J Cebon

BLOOD | AMER SOC HEMATOLOGY | Published : 2005


Dendritic cells (DCs) are being evaluated for cancer immunotherapy due to their unique ability to induce tumor-directed T-cell responses. Here we report that the type of human DC, the mode of activation, and the strategy for delivery of antigen are 3 critical factors for efficient stimulation of tumor-specific CD8+ and CD4+ T cells. Only CD1c+ blood DCs and monocyte-derived DCs (MoDCs) were capable of presenting epitopes of the full-length tumor antigen NY-ESO-1 on both major histocompatibility complex (MHC) class I (cross-presentation) and MHC II, whereas plasmacytoid DCs were limited to MHC II presentation. Cross-presentation was inefficient for soluble protein, but highly efficient for an..

View full abstract